[Federal Register: March 15, 2004 (Volume 69, Number 50)]
[Notices]               
[Page 12178-12179]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15mr04-105]                         

-----------------------------------------------------------------------

Department of Justice

Drug Enforcement Administration

 
Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under Section 1002(a) authorizing the importation of such 
a substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with section 1301.34 of title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on January 30, 
2004, Johnson Matthey Inc., Pharmaceutical Materials, 2003 Nolte Drive, 
West Deptford, New Jersey 08066, made application by renewal to the 
Drug Enforcement Administration to be registered as an importer of the 
basic classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phenylacetone (8501).......................  II
Raw Opium (9600)...........................  II
Concentrate of Poppy Straw (9670)..........  II
------------------------------------------------------------------------

    The firm plans to import the listed controlled substances as raw 
materials for use in the manufacture of bulk controlled substances for 
distribution to its customers.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of the basic classes of controlled substances listed may 
file written comments on or objections to the application described 
above and may, at the same time, file a written request for a hearing 
on such application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States

[[Page 12179]]

Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than April 14, 2004. This procedure is to be conducted 
simultaneously with and independent of the procedures described in 21 
CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous 1975 
notice at 40 FR 43745-46 (September 23, 1975), all applicants for 
registration to import basic class of any controlled substance in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), 
(b), (c), (d), (e), and (f) are satisfied.

    Dated: March 5, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-5779 Filed 3-12-04; 8:45 am]

BILLING CODE 4410-09-M